Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min

Share

Clinical Scorecard: Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPopulation described in the source article.
Care SettingSpecify the type of oncology clinical trials (e.g., phase I, II).

Key Highlights

  • All 16 patients treated with TG4050 remained disease-free after a median follow-up of 41 months.
  • Three of 16 patients in the control group experienced disease recurrence.
  • The vaccine induced detectable T-cell responses in 73.3% of evaluated patients.
  • Responses could be detected more than a year after the final dose.
  • No unexpected safety findings were reported during long-term follow-up.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • C
        • l
        • a
        • r
        • i
        • f
        • y
        • t
        • h
        • e
        • s
        • a
        • f
        • e
        • t
        • y
        • p
        • r
        • o
        • f
        • i
        • l
        • e
        • w
        • i
        • t
        • h
        • s
        • p
        • e
        • c
        • i
        • f
        • i
        • c
        • d
        • a
        • t
        • a
        • o
        • r
        • r
        • e
        • f
        • e
        • r
        • e
        • n
        • c
        • e
        • s
        • .

        Patient & Prescribing Data

        Detail how sequencing informs the vaccine design.

        Clinical Best Practices

        • best_practice_details

        Related Resources & Content

        Original Source(s)

        Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

        • September 16, 2026

        Related Content

        Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma

        Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

        CAR T Before Surgery Improves Glioblastoma Control in Mice

        Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

        • September 7, 2026

        • 3 min